viewInvitrocue Ltd

Invitrocue to discuss its unique Onco-PDO cancer test at Proactive CEO Sessions

The company’s Onco-PDO cancer screening service supports personalised clinical decisions for patients.

New agreement signed focusing on breast cancer models

Invitrocue Ltd’s (ASX:IVQ) Onco-PDO test takes a personalised approach and allows physicians to prescribe the most appropriate treatment regime for a particular type of cancer.

The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a broad panel of chemotherapy drugs to support personalised clinical decisions.

Invitrocue co-founder and executive director Dr. Steven Fang will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

Dr. Steven Fang

READ: Invitrocue signs agreement to develop new breast cancer models for its Onco-PDO test

The company recently signed a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) for the development of new breast cancer models for its Onco-PDO test.

Under the agreement, professor Arial Zeng, an expert in stem cells during mammary development and breast cancer, will help Invitrocue to develop and optimise the protocols for the in vitro culture, propagation and expansion of patient-derived organoids (PDOs) from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC.

The intellectual property (IP) will be jointly owned by both parties and Invitrocue will be granted global commercialisation rights to any IP developed under the agreement.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Also featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Zelda Therapeutics Ltd (ASX:ZLD), Oventus Medical Ltd (ASX:OVN and Infinity Lithium Corporation Ltd (ASX:INF).

Quick facts: Invitrocue Ltd

Price: - AUD

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...


Zelira Therapeutics with Proactive at ASX Small and Mid-Cap Conference

Zelira Therapeutics Ltd (ASX:ZLD) managing director Richard Hopkins speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.  The medicinal cannabis company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing...

on 09/10/2020

2 min read